Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec;50(3):914-22.
doi: 10.1007/s12035-014-8666-0. Epub 2014 Mar 12.

Hyperacetylation of Histone H3K9 Involved in the Promotion of Abnormally High Transcription of the Gdnf Gene in Glioma Cells

Affiliations

Hyperacetylation of Histone H3K9 Involved in the Promotion of Abnormally High Transcription of the Gdnf Gene in Glioma Cells

Zheng-Quan Yu et al. Mol Neurobiol. .

Abstract

The mechanism underlying abnormally high transcription of the glial cell line-derived neurotrophic factor (GDNF) gene in glioma cells is not clear. In this study, to assess histone H3K9 acetylation levels in promoters I and II of the gdnf gene in normal human brain tissue, low- and high-grade glioma tissues, normal rat astrocytes, and rat C6 glioblastoma cells, we employed chromatin immunoprecipitation-polymerase chain reaction (ChIP-PCR), real-time PCR, and a pGL3 dual fluorescence reporter system. We also investigated the influence of treatment with curcumin, a histone acetyltransferase inhibitor, and trichostatin A (TSA), a deacetylase inhibitor, on promoter acetylation and activity and messenger RNA (mRNA) expression level of the gdnf gene in C6 cells. Compared to normal brain tissue, H3K9 acetylation in promoters I and II of the gdnf gene increased significantly in high-grade glioma tissues but not in low-grade glioma tissues. Moreover, H3K9 promoter acetylation level of the gdnf gene in C6 cells was also remarkably higher than in normal astrocytes. In C6 cells, curcumin markedly decreased promoter II acetylation and activity and GDNF mRNA expression. Conversely, all three measurements were significantly increased following TSA treatment. Our results suggest that histone H3K9 hyperacetylation in promoter II of the gdnf gene might be one of the reasons for its abnormal high transcription in glioma cells.

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles

References

    1. Neurosci Res. 2006 Sep;56(1):29-38 - PubMed
    1. Neurotherapeutics. 2009 Jul;6(3):436-46 - PubMed
    1. J Neurochem. 2005 Dec;95(5):1227-36 - PubMed
    1. J Clin Neurosci. 2009 Mar;16(3):427-36 - PubMed
    1. Glia. 2009 Jul;57(9):989-99 - PubMed

Publication types

Substances

Feedback